Advertisement

Clinical Aspects of Thymic Factors in the Treatment of Immunodeficiency Diseases and Neoplasia: Achievements and Failures

  • John R. Hobbs
Part of the NATO ASI Series book series (NSSA, volume 120)

Abstract

Since Jacques Miller showed the importance of the thymus and the term “T-Lymphocyte” was introduced, there followed much basic research, and tor the past 8 years, a variety of thymic factors have become available for therapeutic studies in man. All those currently available have to be given parenterally, and fall into two main groups, (see Tables 1 and 2). Their modes of action (1) will be briefly mentioned, but primarily to stress the importance of the sequential action of a series of factors.

Keywords

Acquire Immune Deficiency Syndrome Chronic Active Hepatitis Severe Combine Immune Deficiency Lepromatous Leprosy Peripheral Blood Mononuclear 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    J. R. Hobbs, N. Byrom, and N. Nagvekar, The Induction of Lymphocyte receptors by Thymic Factors, in: “Peptide Hormones as Mediators in Immunology and Oncology”, R.-D. Hesch, and M. J. Anderson, eds., Raven Press, New York (1985).Google Scholar
  2. 2.
    J. R. Hobbs, N. A. Byrom, J. D. Chambers, S. A. Williamson, and N. Nagvekar, Secondary T-Lymphocyte Deficiencies, in: ‘Thymic Factor Therapy“, N. A. Byrom, and J. R. Hobbs, eds., Raven Press, New York (1984).Google Scholar
  3. 3.
    F. Aiuti and L. Businco, “The Immune System: Functions and Therapy of Dysfunction”. G. Doria, and E. Estakol, eds., Academic Press, New York (1980).Google Scholar
  4. 4.
    J. R. Hobbs, Thymic factors to treat cancer patients, especially those with T-cell deficiencies, in: “Active biological Substances in Cancer Therapy”, in press (1985).Google Scholar
  5. 5.
    N. Byrom, S. Retsas, A. J. Dean, and J. R. Hobbs, The Importance of Dose of Thymosin for the in vitro Induction of T-lymphocytes from Patients with Solid Tumours, Clin. Oncol., 4: 34 (1978).Google Scholar
  6. 6.
    R. Schulof, M. Lloyd, T. Chorba, J. Cox, S. Palaszynski, and A. Goldstein, Immunorestorative and therapeutic effects of synthetic Thymosin-al in patients with lung cancer, in: “Thymic Factor Therapy”, N. A. Byrom, and J. R. Hobbs, eds., Raven Press, New York, (1984).Google Scholar
  7. 7.
    S.-K. Hu, T. L. K. Low, and A. L. Goldstein, Modulation of terminal deoxynucleotidyl transferase activity by thymosin, in: “Thymic Factor Therapy”, N. A. Byrom, and J. R. Hobbs, eds., Raven Press, New York (1984).Google Scholar
  8. 8.
    N. A. Byrom, N. M. Nagvekar, and J. R. Hobbs, Thymic Factor Modulation of Lymphocyte Surface Markers, in: “Thymic Factor Therapy”, N. A. Byrom, and J. R. Hobbs, eds., Raven Press, New York (1984)Google Scholar
  9. 9.
    R. C. D. Staughton, N. A. Byrom, N. M. Nagvekar, and J. R. Hobbs, TP1 Therapy of adult atopic eczema, in: “ Thymic Factor Therapy” N. A. Byrom, and J. R. hobbs, eds., Raven Press, New York (1984)Google Scholar
  10. 10.
    M. E. Osband, E. B. Cohen, D. Hamilton, Z. sen Ho, D. L. Shipman, C. S. Panse, and R. A. Laursen, Suppressin, a calf thymus-derived inducer of histamine H2 receptor-bearing suppressor T-cells: biochemical and biological characteristics, in: “Thymic Factor Therapy”, N. A. Byrom, and J. R. Hobbs, eds., Raven Press, New York (1984).Google Scholar
  11. 11.
    J. Shoham and A. S. Klein, The Potential of Thymic Factors in the Treatment of Cancer, in: “Thymic Factor Therapy”, N. A. Byrom, and J. R. Hobbs, eds., Raven Press, New York (1984).Google Scholar
  12. 12.
    A. Gorski, I. Podobinska, M. Nowaczyk, and G. Korczak-Kowalska, Immunomodulatory effects of thymic factor (TFX) on the interactions between T- and B-cells and their sensitivity to immunosuppressive agents, in: “Thymic Factor Therapy”, N. Y. Byrom, and J. R. Hobbs, eds., Raven Press, New York (1984).Google Scholar
  13. 13.
    A. L. Goldstein, T. L. K. Low, N. R. Hall, P. H. Naylor, and M. M. Zatz, Thymosin and thymosin-like preparations, in: “Thymic Factor Therapy”, N. A. Byrom, and J. R. Hobbs, eds., Raven Press, New York (1984).Google Scholar
  14. 14.
    J. R. Hobbs, S. Malka, and N. A. Byrom, Density and inducibility of T-cell receptors in relation to age of the lymphocyte donor and conditions of culture, Protides Biol. Fluids, 25: 605–610 (1977).Google Scholar
  15. 15.
    J. R. Hobbs, Correction of 34 Genetic Diseases by Displacement Bone Marrow Transplantation, Plasma Ther. Transfus. Technol., 6: 221–246 (1985).Google Scholar
  16. 16.
    F. Aiuti, G. Russo, M. Carbonari, O. Pontesilli, and M. Fiorilli, A rational approach for the use of thymic hormones in viral infection and primary immunodeficiencies, in: “Peptide hormones as mediators in immunology and oncology”, R. D. Hesch, and M. J. Atkinson, eds., Raven Press, New York (1985).Google Scholar
  17. 17.
    M. A. Campbell, Lymphocytes with receptors for IgG and IgM in atopic eczema and their relationship to serum IgE levels, Clinical Allergy, 11: 509–513 (1981).PubMedCrossRefGoogle Scholar
  18. 18.
    K. Ishizaka, Twenty years with IgE: From the identification of IgE to regulatory factors for the IgE response, J. Immunol., 135: i-x (1985).Google Scholar
  19. 19.
    F. Pandolfi, I. Quinti, G. Bonomo, A. Morrone, and M. Cherchi, Cellular Immunity and Thymic Hormone Therapy in Aged Humans and Asymptomatic Homosexuals, in: “Thymic Factor Therapy”, N. A. Byrom, and J. R. Hobbs, eds., Raven Press, New York (1984).Google Scholar
  20. 20.
    J. R. Hobbs, N. Byrom, N. Nagvekar, C. M. E. Rowland Payne, and J. K. Oates, Post-viral T-cell Deficiencies and their Treatment, in: “Progress in Immunodeficiency Research and Therapy 1”, C. Griscelli, and J. Vossen, eds., Elsevier Science Publishers, B. V., Amsterdam (1984).Google Scholar
  21. 21.
    N. A. Byrom, J. R. Hobbs, D. M. Timlin, M. A. Campbell, A. J. Dean, M. Webley, and D. A. Brewerton, T and B Lymphocytes in patients with acute anterior uveitis and ankylosing spondylitis, and in their house-hold contacts, Lancet, 2: 601–603 (1979).PubMedCrossRefGoogle Scholar
  22. 22.
    T. Lindsten, J. K. Seeley, M. Ballow, K. Sakamoto, S. St. Onge, J. Yetz, P. Aman, and D. Purtilo, Immune Deficiency in the X-linked lymphoproliferative syndrome, II. Immunoregulatory T Cell Defects, J. Immunol., 129: 2536–2540 (1982).PubMedGoogle Scholar
  23. 23.
    J. Lindberg, A. Lindholm, P. Lundiz, and S. Iwarson, Trigger factors and HL-A antigens in chronic active hepatitis, Brit. Med. J., 4: 77–79 (1975).CrossRefGoogle Scholar
  24. 24.
    J. R. Hobbs, Disturbance of the immunoglobulins, in: “Scient. Basis Med. Ann. Rev.”, Athlone, London, p. 114 (1966).Google Scholar
  25. 25.
    J. F. Taylor, Lymphocyte transformation in Kaposi’s sarcoma, Lancet, 1: 883–884 (1973).PubMedCrossRefGoogle Scholar
  26. 26.
    F. Barre-Sinoussi, J. C. Chermann, F. Rey, M. T. Nugeyre, S. Chamaret, J. Gruest, C. Dauguet, C. Axler-Blin, F. VezinetBrun, C. Rouzioux, W. Rozenbaum, and L. Montagnier, Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS), Science, 220: 868–871 (1983).PubMedCrossRefGoogle Scholar
  27. 27.
    N. Trainin, Z. T. Handzel, M. Pecht, Y. Varsano, D. W. Beatty, and R. Zaizov, Therapeutic effects of THE in viral diseases, in: “Thymic Factor Therapy”, N. A. Byrom, and J. R. Hobbs, eds., Raven Press, New York (1984).Google Scholar
  28. 28.
    A. P. De Felici, M. A. Longo, E. Giradi, and G. Visco, Thymostimulin therapy in chronic active hepatitis, in: “Thymic Factor Therapy”, N. A. Byrom, and J. R. Hobbs, eds., Raven Press, New York (1984).Google Scholar
  29. 29.
    J. R. Hobbs, N. Byrom, P. Elliott, C.-J. Oon, and S. Retsas, Cell Separators in Cancer Immunotherapy, Exp. Hematol., 5: 95–103 (1977).Google Scholar
  30. 30.
    C. Butterworth, C.-J. Oon, G. Westbury, and J. R. Hobbs, T-Lymphocyte Responses in Patients with malignant Melanoma, Europ. J. Cancer, 10: 639–646 (1974).Google Scholar
  31. 31.
    K. D. Bagshawe, Choriocarcinoma, Arnold, London (1969).Google Scholar
  32. 32.
    B. De Bernardi, G. Pastore, A. Garaventa, C. Rosanda, M. Carli, L. Cordero di Montezemolo, F. Bassani, P. F. Biddau, G. Calculli, C. Guazzelli, G. Loiacono, A. Mancini, C. Pianca, and A. Russo, Thymic Hormone Immunotherapy in Advanced Neuroblastoma, in: “Thymic Factor Therapy”, N. A. Byrom, and J. R. Hobbs, eds., Raven Press, New York (1984).Google Scholar
  33. 33.
    M. G. Bernengo, G. C. Doveil, F. Lisa, M. Meregalli, M. Novelli, and G. Zina, The immunological profile of melanoma and the role of adjuvant thymostimulin immunotherapy in Stage I patients, in: “Thymic Factor Therapy”, N. A. Byrom, and J. R. Hobbs, eds., Raven Press, New York (1984).Google Scholar
  34. 34.
    R. W. Norris, N. A. Byrom, N. M. Nagvekar, A. J. Dean, P. Manhaffey, and J. R. Hobbs, Thymostimulin plus Surgery in the Treatment of Primary Truncal Malignant Melanoma: Preliminary results of a U.K. Multi-centre Clinical Trial, in: “Thymic Factor Therapy”, N. A. Byrom, and J. R. Hobbs, eds., Raven Press, New York (1984).Google Scholar
  35. 35.
    E. Azizi, H. J. Brenner, and J. Shoham, Postsurgical Adjuvant Treatment of Malignant Melanoma Patients by the Thymic Factor Thymostimulin, Arzneim.-Forsch., 34: 1043–1046 (1984).Google Scholar

Copyright information

© Plenum Press, New York 1986

Authors and Affiliations

  • John R. Hobbs
    • 1
  1. 1.Department of Chemical Immunology, Charing Cross and Westminster Medical SchoolWestminster HospitalLondonGB

Personalised recommendations